Skip to main content

Advertisement

SpringerLink
Log in

Favorable outcome associated with an IGF-1 ligand signature in breast cancer

  • Epidemiology
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

The insulin-like growth factor (IGF) axis is fundamentally important in cell growth, development and cancer. We used genomic technologies to better characterize the activity of the IGF axis in human breast cancer and to identify predictors of response to IGF targeted therapies. Analysis of the gene expression patterns and pathway analysis in 204 clinically annotated primary breast cancers were performed and compared to levels of mRNA for IGF ligands and receptors. Pathway activation scores were calculated by Pearson correlation (+1, −1). Network analysis was performed using Ingenuity software. IGF-1 ligand levels were strongly negatively correlated (P < 10−6) with a published IGF-IR activation signature. A signature of high IGF-1 ligand was associated with better prognosis (P = 0.025–1.5 × 10−8) in several public datasets. Pathway analysis revealed upregulation of pathways associated with breast differentiation (adipocyte growth factors, PPAR-gamma) and down-regulation of proliferation pathways (AKT/MAPK) in the IGF-1 ligand high group. Of note, the IGF-1 ligand signature was anti-correlated with IGFIR receptor levels (P = 0.07). In conclusion, a breast tumor-derived signature of high IGF-1 ligand is associated with favorable outcome, in contrast to a previously reported IGF-IR activation signature. The prognostic value of the IGF-I ligand signature is validated in three independent datasets. These signatures should be applied in study of IGF1-R targeted therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Bonneterre J, Peyrat JP, Beuscart R, Demaille A (1990) Prognostic significance of insulin-like growth factor 1 receptors in human breast cancer. Cancer Res 50(21):6931–6935

    PubMed  CAS  Google Scholar 

  2. Blum G, Gazit A, Levitzki A (2003) Development of new insulin-like growth factor-1 receptor kinase inhibitors using catechol mimics. J Biol Chem 278(42):40442–40454

    Article  PubMed  CAS  Google Scholar 

  3. Burtrum D, Zhu Z, Lu D, Anderson DM, Prewett M, Pereira DS et al (2003) A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo. Cancer Res 63(24):8912–8921

    PubMed  CAS  Google Scholar 

  4. Pollak MN, Schernhammer ES, Hankinson SE (2004) Insulin-like growth factors and neoplasia. Nat Rev Cancer 4(7):505–518

    Article  PubMed  CAS  Google Scholar 

  5. Surmacz E (2003) Growth factor receptors as therapeutic targets: strategies to inhibit the insulin-like growth factor I receptor. Oncogene. 22(42):6589–6597

    Article  PubMed  CAS  Google Scholar 

  6. Baserga R, Glazer PM, Turner BC, Haffty BG, Narayanan L, Yuan J et al (1997) Insulin-like growth factor-I receptor overexpression mediates cellular radioresistance and local breast cancer recurrence after lumpectomy and radiation. Cancer Res 57(15):3079–3083

    PubMed  Google Scholar 

  7. Sachdev D, Hartell JS, Lee AV, Zhang X, Yee D (2004) A dominant negative type I insulin-like growth factor receptor inhibits metastasis of human cancer cells. J Biol Chem 279(6):5017–5024

    Article  PubMed  CAS  Google Scholar 

  8. Creighton CJ, Casa A, Lazard Z, Huang S, Tsimelzon A, Hilsenbeck SG et al (2008) Insulin-like growth factor-I activates gene transcription programs strongly associated with poor breast cancer prognosis. J Clin Oncol 26(25):4078–4085

    Article  PubMed  CAS  Google Scholar 

  9. Mu L, Katsaros D, Wiley A, Lu L, de la Longrais I, Smith S et al (2008) Peptide concentrations and mRNA expression of IGF-I, IGF-II and IGFBP-3 in breast cancer and their associations with disease characteristics. Breast Cancer Res Treat [Internet] (cited 2008 Sep 27). http://www.ncbi.nlm.nih.gov/pubmed/18481170

  10. Gentleman R, Carey V, Bates D, Bolstad B, Dettling M, Dudoit S et al (2004) Bioconductor: open software development for computational biology and bioinformatics. Genome Biol 5(10):R80

    Article  PubMed  Google Scholar 

  11. Du P, Kibbe WA, Lin SM (2008) lumi: a pipeline for processing Illumina microarray. Bioinformatics 24(13):1547–1548

    Article  PubMed  CAS  Google Scholar 

  12. Lin SM, Du P, Huber W, Kibbe WA (2008) Model-based variance-stabilizing transformation for Illumina microarray data. Nucleic Acids Res 36(2):e11

    Article  PubMed  Google Scholar 

  13. Smyth GK (2004) Linear models and empirical Bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol. 3(3)

  14. Benjamini Y, Hochberg Y (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B (Methodol) 57(1):289–300

    Google Scholar 

  15. The R Project for Statistical Computing. http://www.r-project.org)

  16. Wang Y, Klijn JGM, Zhang Y, Sieuwerts AM, Look MP, Yang F et al (2005) Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 365(9460):671–679

    PubMed  CAS  Google Scholar 

  17. van de Vijver MJ, He YD, Van’t Veer LJ, Dai H, Hart AAM, Voskuil DW et al (2002) A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347(25):1999–2009

    Article  PubMed  Google Scholar 

  18. Chin K, DeVries S, Fridlyand J, Spellman PT, Roydasgupta R, Kuo W et al (2006) Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell 10(6):529–541

    Article  PubMed  CAS  Google Scholar 

  19. Parker JS, Mullins M, Cheang MCU, Leung S, Voduc D, Vickery T et al (2009) Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 27(8):1160–1167

    Article  PubMed  Google Scholar 

  20. Ingenuity Pathways Analysis (IPA; Ingenuity Systems, Redwood City, CA). http://www.ingenuity.com

  21. Resnik JL, Reichart DB, Huey K, Webster NJ, Seely BL (1998) Elevated insulin-like growth factor I receptor autophosphorylation and kinase activity in human breast cancer. Cancer Res 58(6):1159–1164

    PubMed  CAS  Google Scholar 

  22. Kim H, Litzenburger BC, Cui X, Delgado DA, Grabiner BC, Lin X et al (2007) Constitutively active type I insulin-like growth factor receptor causes transformation and xenograft growth of immortalized mammary epithelial cells and is accompanied by an epithelial-to-mesenchymal transition mediated by NF-{kappa}B and snail. Mol Cell Biol 27(8):3165–3175

    Article  PubMed  CAS  Google Scholar 

  23. Dunn SE, Ehrlich M, Sharp NJ, Reiss K, Solomon G, Hawkins R et al (1998) A dominant negative mutant of the insulin-like growth factor-I receptor inhibits the adhesion, invasion, and metastasis of breast cancer. Cancer Res 58(15):3353–3361

    PubMed  CAS  Google Scholar 

  24. Zhang X, Kamaraju S, Hakuno F, Kabuta T, Takahashi S, Sachdev D et al (2004) Motility response to insulin-like growth factor-I (IGF-I) in MCF-7 cells is associated with IRS-2 activation and integrin expression. Breast Cancer Res Treat 83(2):161–170

    Article  PubMed  CAS  Google Scholar 

  25. Shin A, Ren Z, Shu X, Cai Q, Gao Y, Zheng W (2007) Expression patterns of insulin-like growth factor 1 (IGF-I) and its receptor in mammary tissues and their associations with breast cancer survival. Breast Cancer Res Treat 105(1):55–61

    Article  PubMed  CAS  Google Scholar 

  26. Kato S, Masuhiro Y, Watanabe M, Kobayashi Y, Takeyama KI, Endoh H et al (2000) Molecular mechanism of a cross-talk between oestrogen and growth factor signalling pathways. Genes Cells. 5(8):593–601

    Article  PubMed  CAS  Google Scholar 

  27. Huynh H, Nickerson T, Pollak M, Yang X (1996) Regulation of insulin-like growth factor I receptor expression by the pure antiestrogen ICI 182780. Clin Cancer Res 2(12):2037–2042

    PubMed  CAS  Google Scholar 

  28. Lee AV, Weng CN, Jackson JG, Yee D (1997) Activation of estrogen receptor-mediated gene transcription by IGF-I in human breast cancer cells. J Endocrinol 152(1):39–47

    Article  PubMed  CAS  Google Scholar 

  29. Lee AV, Jackson JG, Gooch JL, Hilsenbeck SG, Coronado-Heinsohn E, Osborne CK et al (1999) Enhancement of insulin-like growth factor signaling in human breast cancer: estrogen regulation of insulin receptor substrate-1 expression in vitro and in vivo. Mol Endocrinol 13(5):787–796

    Article  PubMed  CAS  Google Scholar 

  30. Decensi A, Robertson C, Ballardini B, Paggi D, Guerrieri-Gonzaga A, Bonanni B et al (1999) Effect of tamoxifen on lipoprotein(a) and insulin-like growth factor-I (IGF-I) in healthy women. Eur J Cancer 35(4):596–600

    Article  PubMed  CAS  Google Scholar 

  31. Happerfield LC, Miles DW, Barnes DM, Thomsen LL, Smith P, Hanby A (1997) The localization of the insulin-like growth factor receptor 1 (IGFR-1) in benign and malignant breast tissue. J Pathol 183(4):412–417

    Article  PubMed  CAS  Google Scholar 

  32. Ye J, Liang S, Guo N, Li S, Wu AM, Giannini S et al (2003) Combined effects of tamoxifen and a chimeric humanized single chain antibody against the type I IGF receptor on breast tumor growth in vivo. Horm Metab Res 35(11–12):836–842

    PubMed  CAS  Google Scholar 

  33. Ciarmatori S, Kiepe D, Haarmann A, Huegel U, Tönshoff B (2007) Signaling mechanisms leading to regulation of proliferation and differentiation of the mesenchymal chondrogenic cell line RCJ3.1C5.18 in response to IGF-I. J Mol Endocrinol 38(4):493–508

    Article  PubMed  CAS  Google Scholar 

  34. Ewton DZ, Kansra S, Lim S, Friedman E (2002) Insulin-like growth factor-I has a biphasic effect on colon carcinoma cells through transient inactivation of forkhead1, initially mitogenic, then mediating growth arrest and differentiation. Int J Cancer 98(5):665–673

    Article  PubMed  CAS  Google Scholar 

  35. Rosenthal SM, Cheng ZQ (1995) Opposing early and late effects of insulin-like growth factor I on differentiation and the cell cycle regulatory retinoblastoma protein in skeletal myoblasts. Proc Natl Acad Sci USA 92(22):10307–10311

    Article  PubMed  CAS  Google Scholar 

  36. Wei Y, Chen Y, Li D, Gu R, Wang W (2004) Dual effect of insulin-like growth factor on the apical 70-pS K channel in the thick ascending limb of rat kidney. Am J Physiol Cell Physiol 286(6):C1258–C1263

    Article  PubMed  CAS  Google Scholar 

  37. Lupu R, Cardillo M, Cho C, Harris L, Hijazi M, Perez C et al (1996) The significance of heregulin in breast cancer tumor progression and drug resistance. Breast Cancer Res Treat 38(1):57–66

    Article  PubMed  CAS  Google Scholar 

  38. Marte BM, Jeschke M, Graus-Porta D, Taverna D, Hofer P, Groner B et al (1995) Neu differentiation factor/heregulin modulates growth and differentiation of HC11 mammary epithelial cells. Mol Endocrinol 9(1):14–23

    Article  PubMed  CAS  Google Scholar 

  39. Nagashima T, Shimodaira H, Ide K, Nakakuki T, Tani Y, Takahashi K et al (2007) Quantitative transcriptional control of ErbB receptor signaling undergoes graded to biphasic response for cell differentiation. J Biol Chem 282(6):4045–4056

    Article  PubMed  CAS  Google Scholar 

  40. Staebler A, Sommers C, Mueller SC, Byers S, Thompson EW, Lupu R (1994) Modulation of breast cancer progression and differentiation by the gp30/heregulin [correction of neregulin]. Breast Cancer Res Treat 31(2–3):175–182

    Article  PubMed  CAS  Google Scholar 

  41. Xu F, Yu Y, Le XF, Boyer C, Mills GB, Bast RC (1999) The outcome of heregulin-induced activation of ovarian cancer cells depends on the relative levels of HER-2 and HER-3 expression. Clin Cancer Res 5(11):3653–3660

    PubMed  CAS  Google Scholar 

  42. Hallstrom TC, Mori S, Nevins JR (2008) An E2F1-dependent gene expression program that determines the balance between proliferation and cell death. Cancer Cell 13(1):11–22

    Article  PubMed  CAS  Google Scholar 

  43. Mueller E, Sarraf P, Tontonoz P, Evans RM, Martin KJ, Zhang M et al (1998) Terminal differentiation of human breast cancer through PPAR[gamma]. Mol Cell 1(3):465–470

    Article  PubMed  CAS  Google Scholar 

  44. Massagué J (2008) TGF[beta] in cancer. Cell 134(2):215–230

    Article  PubMed  Google Scholar 

  45. Oft M, Peli J, Rudaz C, Schwarz H, Beug H, Reichmann E (1996) TGF-beta1 and Ha-Ras collaborate in modulating the phenotypic plasticity and invasiveness of epithelial tumor cells. Genes Dev 10(19):2462–2477

    Article  PubMed  CAS  Google Scholar 

  46. Danielpour D, Song K (2006) Cross-talk between IGF-I and TGF-[beta] signaling pathways. Cytokine Growth Factor Rev 17(1–2):59–74

    Article  PubMed  CAS  Google Scholar 

  47. Jassem J, Langer CL, Karp DD, Mok T, Novello S, Park K, Strausz J, Benner RJ, Green S, Gualberto A (2010) Randomized, open label, phase III trial of figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin in patients with non-small cell lung cancer (NSCLC). American Society of Clinical Oncology Annual Meeting 2010. Abstract #7500, Chicago

Download references

Author information

Author notes

  1. Lina Mu

    Present address: Department of Social and Preventive Medicine, School of Public Health and Health Professions, University at Buffalo, The State University of New York, Buffalo, NY, 14214, USA

Authors and Affiliations

  1. Department of Epidemiology and Public Health, Yale University School of Medicine, New Haven, CT, 06520-8034, USA

    Lina Mu, Lingeng Lu & Herbert Yu

  2. Department of Pathology, Yale University School of Medicine, New Haven, CT, 06520-8034, USA

    David Tuck & Sudhir Perincheri

  3. Gynecologic Oncology and Breast Cancer Unit, Department of Obstetrics and Gynecology, University of Turin, Turin, Italy

    Dionyssios Katsaros, Guido Menato & Luca Scarampi

  4. Department of Pediatrics, Yale University School of Medicine, New Haven, CT, 06520-8034, USA

    Vincent Schulz

  5. Department of Pathology, S’Anna Hospital, Turin, Italy

    Dionyssios Katsaros, Guido Menato & Luca Scarampi

  6. Department of Medicine, Yale Cancer Center, Yale University School of Medicine, 333 Cedar St., WWW213, New Haven, CT, 06520-8034, USA

    Lyndsay Harris

  7. Case Western Reserve University, Cleveland, OH, USA

    Lyndsay Harris

Authors
  1. Lina Mu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. David Tuck
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Dionyssios Katsaros
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Lingeng Lu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Vincent Schulz
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Sudhir Perincheri
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Guido Menato
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Luca Scarampi
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Lyndsay Harris
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Herbert Yu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lyndsay Harris.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (DOC 93 kb)

Supplementary material 2 (PPT 238 kb)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mu, L., Tuck, D., Katsaros, D. et al. Favorable outcome associated with an IGF-1 ligand signature in breast cancer. Breast Cancer Res Treat 133, 321–331 (2012). https://doi.org/10.1007/s10549-012-1952-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10549-012-1952-5

Keywords

Search

Navigation